Here are a few featured publications from our group. A complete list of publications is available here.
JAMA OPEn 2024
Prenatal Care Initiation and Exposure to Teratogenic Medications
Prenatal care commonly occurred after exposure to teratogenic medications during pregnancy and after strict abortion cutoffs, prohibiting medication risk-benefit assessments and discussion of options, including pregnancy termination if concerns about teratogenic effects arise.
JAMA OPen 2024
Prenatal Exposure to Valproic Acid Across Various Indications for Use
Pregnancy rates during valproic acid treatment remained unchanged during the 15-year study and were more than doubled among users with mood disorder or migraine compared with epilepsy. Contraception use among users was uncommon, raising concerns about current risk mitigation efforts.
AJOG 2023
Gadolinium and risk of fetal or neonatal death
Use of gadolinium-enhanced MRI during pregnancy did not result in increased risk of stillbirth or sudden infant death among more than 10 million evaluated pregnancies. We also found no association with the need for neonatal intensive care. Although long-term risks were not evaluated, our null findings are reassuring.
Ann Intern med 2023
Effectiveness of topiramate risk mitigation
While the REMS for Qsymia showed significant decreases in prenatal exposure risk, generic topiramate had similar rates as other weight loss products.
Clin Inf Dis 2023
Quinolone ear drops and tendon ruptures
This study continues a pretty crazy story about tissue toxicity of quinolones, which appears to potentially manifest at extremely small doses.
JAMA Network open
Dynamics of antiplatelet therapy
Treatment preferences have shifted to newer agents but de-escalation to clopidogrel is increasing as well. Bleeding risk appears to have a limited role in these therapeutic choice though.
Pediatrics 2022
Watchful Waiting for Acute Otitis Media
Adoption of watchful waiting for management of uncomplicated, nonrecurrent AOM was limited and stagnant and driven by clinician rather than patient factors.
AJOG 2022
Prenatal Exposure to Teratogenic Medications
Fetuses in more than 1 in 16 pregnancies continued to be exposed to teratogenic drugs during the past decade. Drugs with Risk Evaluation and Mitigation Strategies imposed a small burden of prenatal exposure.
Basic Clin Pharmacol Toxicol 2022
Triangulation of pharmacoepidemiology and laboratory science
Triangulation of mechanistic and RWE studies allowed incremental progress toward robust evidence on otic quinolone toxicity.
JAMA Intern Med 2021
US FDA Removal of Indications for Use of Oral Quinolones and Prescribing Trends
Although label changes and their announcements resulted in reduction on oral quinolone use, opportunities for improvement remain
Diabetes care 2021
Glucagon-Like Peptide 1 Receptor Agonists and Chronic Lower Respiratory Disease
GLP-1RA users had fewer CLRD exacerbations in comparison with DPP-4I users. Considering both plausible mechanistic pathways and this real-world evidence, potential beneficial effects of GLP-1RA may be considered in selection of an antidiabetes treatment regimen.
Drug Safety 2021
Real-World Fetal Exposure to Acne Treatments
Fetal exposure to acne treatments varied according to levels of teratogenicity, with reduced rates among users of isotretinoin and to a lesser extent doxycycline/minocycline. Teenagers had low pregnancy rates but less pronounced differences in fetal exposure across acne treatments.
Epidemiology 2021
Pharmacoepidemiologic Approach to Evaluate Real-world Effectiveness of Hormonal Contraceptives in the Presence of Drug-drug Interactions
Measurement of conception in claims data had adequate accuracy to uncover a strong drug–drug interaction, offering promise for broader application in comparative effectiveness studies on hormonal contraceptives.
CPT 2020
Risk of opioid overdose associated with concomitant use of opioids and skeletal muscle relaxants
Short-term use of select SMRs in combination with opioids appears safe. Caution should be exercised with long-term use, use of baclofen or carisoprodol, high-dose opioids, and benzodiazepines.
